EV-miRNAs from breast cancer patients of plasma as potential prognostic biomarkers of disease recurrence

被引:0
作者
Causin, Rhafaela Lima [1 ]
Polezi, Mariana Regatieri [1 ]
Freitas, Ana Julia Aguiar de [1 ]
Calfa, Stephanie [1 ]
Altei, Wanessa Fernanda [1 ,2 ]
Dias, Julia Oliveira [1 ]
Laus, Ana Carolina [1 ]
Pessoa-Pereira, Danielle [1 ]
Komoto, Tatiana Takahasi [1 ]
Evangelista, Adriane Feijo [1 ,3 ]
Souza, Cristiano de Padua [4 ]
Reis, Rui Manuel [1 ,5 ,6 ]
Marques, Marcia Maria Chiquitelli [1 ]
机构
[1] Barretos Canc Hosp, Mol Oncol Res Ctr, BR-14784400 Barretos, SP, Brazil
[2] Barretos Canc Hosp, Radiat Oncol Dept, BR-14784400 Barretos, SP, Brazil
[3] Fundacao Oswaldo Cruz, Sergio Arouca Natl Sch Publ Hlth, BR-21040361 Rio De Janeiro, Brazil
[4] Barretos Canc Hosp, BR-14784400 Barretos, SP, Brazil
[5] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, P-4710057 Braga, Portugal
[6] PT Govt Associate Lab, ICVS, 3Bs, P-4710057 Braga, Portugal
基金
巴西圣保罗研究基金会;
关键词
Breast cancer; Extracellular vesicles; MicroRNA; Biomarkers; Disease recurrence; MOLECULAR PORTRAITS; P53; MDM4; MICRORNAS; PATHWAY;
D O I
10.1016/j.heliyon.2024.e33933
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Extracellular vesicles (EVs), ubiquitously released by blood cells, facilitate intercellular communication. In cancer, tumor-derived EVs profoundly affect the microenvironment, promoting tumor progression and raising the risk of recurrence. These EVs contain miRNAs (EVmiRNAs), promising cancer biomarkers. Characterizing plasma EVs and identifying EV-miRNAs associated with breast cancer recurrence are crucial aspects of cancer research since they allow us to discover new biomarkers that are effective for understanding tumor biology and for being used for early detection, disease monitoring, or approaches to personalized medicine. This study aimed to characterize plasma EVs in breast cancer (BC) patients and identify EV-miRNAs associated with BC recurrence. Methods: This retrospective observational study included 24 BC patients divided into recurrence (n = 11) and non-recurrence (n = 13) groups. Plasma EVs were isolated and characterized. Total RNA from EVs was analyzed for miRNA expression using NanoString 's nCounter (R) miRNA Expression Assays panel. MicroRNA target prediction used mirDIP, and pathway interactions were assessed via Reactome. Results: A stronger presence of circulating EVs was found to be linked with a less favorable prognosis (p = 0.0062). We discovered a distinct signature of EV-miRNAs, notably including miR19a-3p and miR-130b-3p, which are significantly associated with breast cancer recurrence.Furthermore, miR-19a-3p and miR-130b-3p were implicated in the regulation of PTEN and MDM4, potentially contributing to breast cancer progression. A notable association emerged, indicating a high concentration of circulating EVs predicts poor prognosis (p = 0.0062). Our study found a distinct EV-miRNA signature involving miR-19a-3p and miR-130b-3p, strongly associated with disease recurrence. We also presented compelling evidence for their regulatory roles in PTEN and MDM4 genes, contributing to BC development. Conclusion: This study revealed that increased plasma EV concentration is associated with BC recurrence. The prognostic significance of EVs is closely tied to the unique expression profiles of miR-19a-3p and miR-130b-3p. These findings underscore the potential of EV-associated miRNAs as valuable indicators for BC recurrence, opening new avenues for diagnosis and treatment exploration.
引用
收藏
页数:15
相关论文
共 52 条
[1]   Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer [J].
Aguiar de Freitas, Ana Julia ;
Causin, Rhafaela Lima ;
Varuzza, Muriele Bertagna ;
Calfa, Stephanie ;
Trovo Hidalgo Filho, Cassio Murilo ;
Komoto, Tatiana Takahasi ;
Souza, Cristiano de Padua ;
Chiquitelli Marques, Marcia Maria .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (17)
[2]   MicroRNA history: Discovery, recent applications, and next frontiers [J].
Almeida, Maria I. ;
Reis, Rui M. ;
Calin, George A. .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2011, 717 (1-2) :1-8
[3]  
[Anonymous], The Cancer Gene Index Gene-Disease and Gene-Compound XML Documents - ICR - Cancer Gene Index - NCI Wiki Internet
[4]   MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib [J].
Bordinhao, A. L. R. ;
Evangelista, A. F. ;
Oliveira, R. J. S. ;
Macedo, T. ;
Silveira, H. C. ;
Reis, R. M. ;
Marques, M. M. .
ONCOLOGY REPORTS, 2016, 36 (06) :3197-3206
[5]   Endocrine resistance in breast cancer - An overview and update [J].
Clarke, Robert ;
Tyson, John J. ;
Dixon, J. Michael .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 418 :220-234
[6]   p53 as a Marker of Prognosis in African-American Women with Breast Cancer [J].
Dookeran, Keith A. ;
Dignam, James J. ;
Ferrer, Karen ;
Sekosan, Marin ;
McCaskill-Stevens, Worta ;
Gehlert, Sarah .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (05) :1398-1405
[7]   The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN [J].
Egawa, Hiroshi ;
Jingushi, Kentaro ;
Hirono, Takayuki ;
Ueda, Yuko ;
Kitae, Kaori ;
Nakata, Wataru ;
Fujita, Kazutoshi ;
Uemura, Motohide ;
Nonomura, Norio ;
Tsujikawa, Kazutake .
SCIENTIFIC REPORTS, 2016, 6
[8]   Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer [J].
Evangelista, Adriane F. ;
Oliveira, Renato J. ;
O. Silva, Viviane A. ;
D. C. Vieira, Rene A. ;
Reis, Rui M. ;
C. Marques, Marcia M. .
BMC CANCER, 2021, 21 (01)
[9]   Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo [J].
Francoz, S ;
Froment, P ;
Bogaerts, S ;
De Clercq, S ;
Maetens, M ;
Doumont, G ;
Bellefroid, E ;
Marine, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (09) :3232-3237
[10]   Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA [J].
Gao, Jianjian ;
Zhang, Qingyun ;
Xu, Jianjun ;
Guo, Lijuan ;
Li, Xuefeng .
CHINESE JOURNAL OF CANCER RESEARCH, 2013, 25 (06) :743-748